Recombinant haemoglobin 1.1

Drug Profile

Recombinant haemoglobin 1.1

Alternative Names: Human recombinant haemoglobin - Baxter Healthcare; Optro; Recombinant haemoglobin 1.1- Baxter Healthcare; Recombinant human haemoglobin - Somatogen; rHb 1.1

Latest Information Update: 06 Dec 2001

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Baxter Healthcare Corporation
  • Class
  • Mechanism of Action Oxygen carriers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Hypovolaemia

Most Recent Events

  • 06 Dec 2001 Discontinued-Clinical for Hypovolaemia in Canada (IV-infusion)
  • 06 Dec 2001 Discontinued-Clinical for Hypovolaemia in USA (IV-infusion)
  • 28 Jun 2001 No-Development-Reported for Hypovolaemia in Canada (IV-infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top